Schrödinger Quarterly Earnings Report Review

Schrödinger (NASDAQ:SDGR - Get Free Report) announced its earnings results for the latest quarter on Wednesday. The company reported an earnings per share (EPS) of ($0.55), which fell short of analysts' consensus expectation of ($0.35) by a margin of ($0.20). This indicates that the company did not perform as well as analysts had predicted.

In addition to the disappointing EPS figures, Schrödinger reported a negative net margin of 91.84%, highlighting ongoing challenges in profitability. Furthermore, the company showed a negative return on equity of 35.77%, which is a significant concern for investors.

Schrödinger Stock Performance

Following the earnings announcement, shares of Schrödinger showed a slight increase of 3.1%, trading up $0.65 to reach $21.70 during mid-day transactions. A total of 1,089,725 shares changed hands, which is higher than the average trading volume of 1,003,185. For reference, Schrödinger has a 50-day simple moving average of $22.19 and a 200-day simple moving average of $20.55. Over the past year, the stock hit a low of $16.67 and a high of $33.63. Currently, the company has a market capitalization of $1.58 billion and a price-to-earnings ratio of -9.27, which reflects challenges in profitability.

Analysts' Insights on Schrödinger

Several research analysts have weighed in on Schrödinger's stock performance. On November 13th, BMO Capital Markets raised their target price for Schrödinger from $25.00 to $28.00 and assigned an "outperform" rating. Similarly, KeyCorp increased their target price from $25.00 to $27.00, providing an "overweight" rating in a report dated January 24th.

Currently, three analysts have given a hold rating, six have rated it as a buy, and one has indicated a strong buy for the stock. Overall, MarketBeat’s data reveals a consensus rating of "Moderate Buy" with an average price target of $32.11 for Schrödinger.

Company Overview

Schrödinger, Inc. operates in the field of drug development through its physics-based computational platform that facilitates the discovery of new molecules for drug and material applications. The company is split into two main segments: Software and Drug Discovery. The Software segment specializes in licensing its technologies aimed at transforming molecular discovery for both the life sciences and materials science industries.

Earnings, Stock, Schrödinger